

## Topotecan (Oral)

**INDICATION:** Relapsed small cell lung cancer patients for whom re-treatment with 1<sup>st</sup> line regimen or CAV regimen is not considered appropriate

Performance status of 0 or 1

### Prior to a course of chemotherapy

- FBC, U&Es, LFTs
- Neuts > 1.5
- Plts > 100
- Hb > 9
- Serum Cr < 133 and/or Cl<sub>Cr</sub> > 60
- Not recommended in moderate or severe liver failure

### Prior to each cycle

- FBC, U&Es (see dose modifications below)

### Topotecan\* 2.3mg/m<sup>2</sup> daily for 5 days

#### Every 21 days for 4-6 cycles

Additional meds:

Metoclopramide 10mg tds prn for nausea

Loperamide 4mg stat then 2mg prn after each loose stool (max 16mg/day)

\*1mg and 0.25mg capsules

#### Dose modification for haematological toxicity

- |   |   |
|---|---|
| • Neutrophils < 1.0 or platelets < 100  | Delay treatment by 7 days   |
| • Severe Neutropenia (neutrophils < 0.5 for > 7days), febrile neutropenia or treatment delays due to neutropenia: | Reduce dose to 1.9 mg/m <sup>2</sup> /day for subsequent treatments |
| • If platelets fall below 25 or If at risk of bleeding with low platelets   | Transfuse platelets and reduce dose as above for subsequent cycles  |

Dose modification for diarrhoea

- **Grade 3 or 4**

**Reduce dose by 0.4mg/m<sup>2</sup>/day**

**If dose reduction required below 1.5mg/m<sup>2</sup>/day then discontinue**

**Expected toxicities:**

**Myelosuppression (severe)**

**Diarrhoea (severe)**

**Vomiting**

**Dyspnoea**

**Neutropenic colitis**

**Interstitial lung disease (ILD):** Patients should be monitored for new onset cough, fever, SOB and/or hypoxia. Any new symptoms of this nature suggestive of ILD, if confirmed, in patients treated with Topotecan should immediately discontinue therapy and appropriate treatment initiated.

The risk factors for Topotecan induced ILD are:

Previous history of ILD, Pulmonary fibrosis, lung cancer, thoracic exposure to radiation, use of pneumotoxic drugs and/or colony stimulating factors.

**This protocol has been reviewed by the Lancashire & South Cumbria Lung Oncology Consultants' Group and responsibility for the protocol lies with the Head of Service.**

**Date: March 2017**

**Next review: March 2019**